TrialBlood2014

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Jeffrey E Lancet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.